Report Categories
View AllRecent Articles
View All
FNLC First releases Q1 2026 earnings of 80 cents per share stock rises 151 percent in regular trading
SLXN Silexion Therapeutics posts wider than expected Q4 2025 loss pushing shares 301 percent lower in todays trading
Why Lexeo Therapeutics LXEO ability to generate cash matters Smart Money Active 20260506
INNE Summit leadership reaffirms preferred dividend commitments as it refines its premium hotel portfolio strategy